Julphar receives the Jordan Food and Drug Administration (JFDA)delegation.
Dr. Essam Farouk, CEO of Julphar receives the Director General of the Food and Drug Authority (JFDA), and Chairman of the Pharmaceutical Manufacturing Committee in the Hashemite Kingdom of Jordan, Prof. Dr. Nizar Mahmoud Mahidat and a delegation of the JFDA on Monday, July 5, 2021 at Julphar head office in Ras Al-Khaimah, UAE. The visit comes in line with the JFDA framework of evaluating Hayat-Vax, COVID-19 vaccine manufacturing plants, Julphar 5 & Julphar 8.
During the visit, Dr. Essam Farouk accompanied Prof. Dr. Nizar Mhaidat and his accompanying delegation on a tour to all Julphar manufacturing facilities, including the state of the art Hayat-Vax vaccine production lines to review the work mechanism.
Commenting on the visit, Dr. Essam Farouk said: "We were honored to receive Prof. Dr. Nizar Mahmoud Mhaidat and his accompanying delegation at Julphar's headquarter, as part of the inspection process of the manufacturing plants of Julphar, and evaluating Julphar Vaccine plant’s commitment to good manufacturing Practices and its adhering to COVID-19 vaccine international standards.”
It is worth noting that the Sinopharm vaccine was approved by the World Health Organization to combat the spread of the Covid-19 virus.